Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial
Top Cited Papers
- 1 August 2004
- journal article
- clinical trial
- Published by Wolters Kluwer Health in PAIN®
- Vol. 110 (3) , 628-638
- https://doi.org/10.1016/j.pain.2004.05.001
Abstract
A randomized, double-blind, placebo-controlled, parallel-group, multicenter, 8-week trial (with subsequent open-label phase) evaluated the effectiveness of pregabalin in alleviating pain associated with diabetic peripheral neuropathy (DPN). For enrollment, patients must have had at baseline: 1- to 5-year history of DPN pain; pain score > or =40 mm (Short-Form McGill Pain Questionnaire [SF-MPQ] visual analogue scale); average daily pain score of > or =4 (11-point numerical pain rating scale [0 = no pain, 10 = worst possible pain]). One hundred forty-six (146) patients were randomized to receive placebo (n = 70) or pregabalin 300 mg/day (n = 76). Primary efficacy measure was endpoint mean pain score from daily patient diaries (11-point numerical pain rating scale). Secondary measures included SF-MPQ scores; sleep interference scores; Patient and Clinical Global Impression of Change (PGIC and CGIC); Short Form-36 (SF-36) Health Survey scores; and Profile of Mood States (POMS) scores. Safety assessment included incidence and intensity of adverse events, physical and neurological examinations, and laboratory evaluations. Pregabalin produced significant improvements versus placebo for mean pain scores (P < 0.0001); mean sleep interference scores SF-36 Bodily Pain subscale (P < 0.0001); total SF-MPQ score (P < 0.01); SF-36 Bodily Pain subscale (P < 0.03); PGIC (P = 0.001); and Total Mood Disturbance and Tension-Anxiety components of POMS (P < 0.03). Pain relief and improved sleep began during week 1 and remained significant throughout the study (P < 0.01). Pregabalin was well tolerated despite a greater incidence of dizziness and somnolence than placebo. Most adverse events were mild to moderate and did not result in withdrawal. Pregabalin was safe and effective in decreasing pain associated with DPN, and also improved mood, sleep disturbance, and quality of life.Keywords
This publication has 31 references indexed in Scilit:
- Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scalePAIN®, 2001
- Gabapentin inhibits the substance P-facilitated K+-evoked release of [3H]glutamate from rat caudal trigeminal nucleus slicesPain, 2001
- Antidepressants and Anticonvulsants for Diabetic Neuropathy and Postherpetic Neuralgia: A Quantitative Systematic ReviewJournal of Pain and Symptom Management, 2000
- Gabapentin (neurontin) and S‐(+)‐3‐isobutylgaba represent a novel class of selective antihyperalgesic agentsBritish Journal of Pharmacology, 1997
- The Novel Anticonvulsant Drug, Gabapentin (Neurontin), Binds to the α2δ Subunit of a Calcium ChannelJournal of Biological Chemistry, 1996
- The epidemiology and treatment of depression when it coexists with somatoform disorders, somatization, or painGeneral Hospital Psychiatry, 1992
- The MOS 36-ltem Short-Form Health Survey (SF-36)Medical Care, 1992
- Development of a sleep diary for chronic pain patientsJournal of Pain and Symptom Management, 1991
- Chronic and Remitting Painful Diabetic Polyneuropathy: Correlations With Clinical Features and Subsequent Changes in NeurophysiologyDiabetes Care, 1988
- Sleep disturbance in pain clinic patientsPain, 1985